Sign in
Taking people in NetherlandsPhase 1

Tests a PET imaging agent in adults with advanced breast or lung cancer

Tests a PET scan agent, [68Ga]Ga-DWJ155, in adults with advanced breast or lung cancer.

Key facts

Who runs it
Novartis Pharma AG
Where
Groningen, NetherlandsSee the site
Registry title
A phase I study of [68Ga]Ga-DWJ155 in patients with advanced breast and NSCLC cancers
Status
Recruiting
Phase
Phase 1
People taking part
36 people, planned
Started
26 Jun 2026
Expected to end
31 Oct 2028
Type of study
Interventional
Record updated
12 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced breast cancer or advanced non-small cell lung cancer (NSCLC) to test an imaging agent, [68Ga]Ga-DWJ155.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Advanced breast cancer or advanced NSCLC.

Main reasons for not taking part

  • Healthy volunteers cannot join.

Where in Netherlands

  • Pharmaceutical Research Associates Group B.V.Groningen, NetherlandsTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests a PET imaging agent in adults with advanced breast or lung cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
12 August 2026